

Disclaimer

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.



Go to www.slido.com
CMDJune2021

WACKER

Agenda for Today

Agenda

10:00 - 11:00 AM CEST

R&D / BIOSOLUTIONS

Our Speakers



Christian Hartel
CEO



Tobias Ohler
CFO



Susanne
Leonhartsberger
President
BIOSOLUTIONS



Christoph Kowitz
Head of R&D

WACKER: Virtual CMD Series Roadmap

June 2020

WACKER Strategy Update - Delivering on our 5 Targets



Dec 2020

SILICONES & POLYMERS - Specialties Growth & Performance Based Substitution



Today

BIOSOLUTIONS and R&D - Accelerated Growth with Cutting-Edge Technologies



Q4 2021

ESG & POLYSILICON - Leading CO₂ Abatement Technologies



Q1 2022

WACKER Strategy Update - Entering a New Phase with New Group Targets & Ambitions




Solid Track Record on Achieving Our 5 Targets...


5 Targets

1. CapEx – Extend Leverage Phase ✓
2. Grow Above Chemical Production ✓
3. Focus Strongly on Sustainability ✓
4. Sustain Attractive Margins Over the Cycle ✓
5. Generate Cash ✓

Specialties Strategy Improves Margins



Strong Group NCF on Lower Capital Intensity



... Ready for the Next Step

1) Chemicals = SILICONES, POLYMERS and BIOSOLUTIONS 2) Cash conversion = Net cash flow / Group EBITDA

Trading Update

For Q2 2021 WACKER Expects Sales of ~€1.5bn with an EBITDA of €300-350m

SILICONES

- ▶ Strong demand for specialties across diversified industries
- ▶ Continued specialties growth supported by mid- and downstream investments

POLYMERS

- ▶ Continued demand growth in DPP¹ and adhesives
- ▶ Price increases and surcharges to address unprecedented rise in raw material costs

BIOSOLUTIONS

- ▶ BioPharma continues strong, but significant ramp and integration costs in Q2 following Amsterdam expansion & acquisition of pDNA specialist in the US

POLYSILICON

- ▶ Strong solar volumes, lean inventory levels and increasingly higher prices
- ▶ Strong demand from semiconductors

1) DPP = Dispersible Polymer Powders

WACKER

CREATING TOMORROW'S SOLUTIONS



WACKER R&D
Christoph Kowitz

Innovation is Key to WACKER's Business Strategy

Innovation Figures

3.3%

of 2020 group sales
spent in R&D

750

Employees
in R&D

4,200

Active patents

1,400

Pending patent
applications


85-100

Inventions annually
applied for¹

45

Scientific
collaborations

R&D Spend



- Product development
- Process & product optimization
- Basic research
- Technology development

Strong Market Presence & Technology Development in the Regions



- ▶ Globally: 23 Technical Centers and R&D Centers
- ▶ Germany: Consortium for Electrochemical Industry
- ▶ India: Consumer Care & Textiles
- ▶ Korea: Center of Electronics Excellence
- ▶ Shanghai: Competence Center for Cement & Concrete
- ▶ US: Silicones R&D Center

1) Over the last 5 years

Innovation Focused Across Three Pillars Driving Growth & Sustainability

Applications

- ▶ New applications with existing technologies



Silane-Modified Polymers



Optical Bonding

Products

- ▶ New products for existing & new markets




Si Anode Battery



Eco Products

Processes

- ▶ New processes to increase yields & lower emissions



RHYME¹ Bavaria



ESETEC®

1) RHYME = Renewable Hydrogen and Methanol

Applications

Advanced Adhesives Drives Strong Market Growth

Silane-Modified Polymers with Excellent Performance & Substitution Drive

Performance

Excellent adhesion & elasticity for nearly all material combinations

Environment

Unique α -technology enables tin-, plasticizer-, and isocyanate-free systems

Fast-Growing Market

\$2.8bn SMP market¹ with >12% CAGR

Each Product Generation

Increases number of addressable markets



GENIOSIL® STP-E



GENIOSIL® XB



GENIOSIL® XT



GENIOSIL® XM

1) SMP = Silane Modified Polymer; Source: LP Information Market, Study, April 2020, Global Hybrid Adhesive & Sealant Market Growth 2020 – 2025

Applications

Best-in-Class LUMISIL® OCR for Optical Bonding Based on 2K Silicones

Market leader in UV-Curable Optical Clear Resins (OCRs) Through New Standard

Attractive Growth Opportunity

Consumer electronics, autonomous driving, smart buildings

Superior Performance

High clarity & no yellowing, best environmental stability

Processability Benchmark

Cross-linkable thermally or with UV light, tailored curing behavior and pot life

Expanding Applications

Provide solutions for next generation technologies



LUMISIL® UV



Large Displays



IT & Mobile Displays



Smart Glass


Products

Silicon Containing Materials for Anodes in Lithium-ion Batteries


Materials¹ Currently Being Tested by Cell Manufacturers

Some approaches to incl. silicon in lithium-ion battery anode

... as μm particles from special grades with tailored surfaces



... in nano-scale embedded in carbon matrix, e.g. from pyrolysis of polymer precursor



Silicon surface area

Smaller

Larger

Availability
Producibility
Scalability

More
straight
forward

More
Complex

Potential
cycle life

Shorter

Longer

Potential
cell
expansion

Larger

Smaller

Feedback from OEMs and Cell Manufacturers Sets Development Path

- ▶ Higher energy density than status quo
- ▶ Cycle life shows encouraging developments
- ▶ Added benefit of fast charging under investigation
- ▶ WACKER & Nexeon offer different product classes to potential customers
- ▶ These product classes are broadly covered by patent applications in important jurisdictions

Silicon seems to be the “Only Game in Town” to increase the capacity of the anode

1) Developed by WACKER & Nexeon

Products

First-Ever Silicone Sealants & Dispersible Polymer Powders Based on Renewables

ELASTOSIL® eco Silicone



- ▶ Silicone sealant produced via mass balance approach
- ▶ Methanol feedstock: sugar beets, straw and grass




VINNECO® Polymer Powder



- ▶ Suitable for dry-mix mortars for ETICS¹ or waterproofing membranes
- ▶ Bio-acetic acid feedstock: wood / hemicellulose



Mass Balance Approach




- ▶ Performance & processing identical to traditional product
- ▶ Progressive increase of renewable raw materials used

1) ETICS: External Thermal Insulation Composite Systems

Process

RHYME Bavaria – Renewable Hydrogen and Methanol Bavaria



Process

Proprietary ESETEC[®] *E. coli* Platform for Best-in-Class Rec. Protein Production

WACKER ESETEC[®] *E. coli* Strains Platform for Diverse Biopharmaceuticals & Nutraceuticals

Ever-Broadening Applications

Proteins like enzymes, hormones; carbohydrates; amino acids

Fast-Growing Market


Double-digit growth in dynamic pharma market segments

Focus on Yield & Easy Processing


Balancing cell stability, level of expression, folding fidelity, secretion

Proprietary ESETEC[®] Strains

Improvement & evolution for over a decade with broad IP protection




All-Purpose "Leaky" Strain



"Controlled Release"



Focus on Cell Stability



Focus on Secretion



CREATING TOMORROW'S SOLUTIONS



WACKER
BIOSOLUTIONS
Susanne Leonhartsberger

BIOSOLUTIONS at a Glance

Accelerated Growth in BioPharma & BioIngredients



BioPharma:

- ▶ GMP contract manufacturing of biologics, vaccines, live microbials, mRNA, pDNA
- ▶ Efficient & cost saving microbial technologies

BioIngredients:

- ▶ Nutraceuticals, Cysteine, Cyclodextrins
- ▶ Fermentation technologies with high purity & free of animal products

Focus on Efficiency & Cash in Life Science Chemicals




Gum:

- ▶ Food-grade polyvinyl acetate for gum base

Advanced Intermediates:

- ▶ Acetylacetone, organosilanes & fine chemicals

BIOSOLUTIONS Sales



- ▶ Leveraging technologies for biotechnology-based growth

Ambition: €1bn Sales in BIOSOLUTIONS

Strategy



- ▶ Expand BioPharma capacities to support strong growth
- ▶ Establish WACKER as a leading mRNA & pDNA CDMO¹
- ▶ Grow BioIngredients product portfolio
- ▶ Innovation and M&A to accelerate growth
- ▶ Generate cash in Life Science Chemicals

Our Growth and Earnings Ambition

**€1bn Sales in
BIOSOLUTIONS
with >25% EBITDA
by 2030**

1) CDMO= Contract Development and Manufacturing Organization

WACKER's BioIngredients and Nutraceuticals Business

Fermentation-Based Solutions for a Wide Range of Applications to Meet Growing Consumer Trends

Healthy Living Trends

Renewable Raw Materials



Antioxidants



Anti-inflammatory

Fermentation Technologies

Broad Range of Applications



Higher Bioavailability



Optimizing Taste

BiIngredients

WACKER is a Leading Supplier of L-Cysteine from Renewable Raw Materials

Broad Range of Applications



- ▶ Flavors: savory flavors
- ▶ Food: dough softening
- ▶ Supplement: infant nutrition
- ▶ Personal care: hair treatment & perms
- ▶ Pharma: cough medicine, protein refolding & cell culture media

Sustainable Process



- ▶ Fermentation process based on renewable raw materials
- ▶ 96% less HCl consumption¹ than traditional process
- ▶ Highest purity

Free of Animal Products




- ▶ Vegetarian & vegan
- ▶ Kosher & halal
- ▶ No allergen labeling required
- ▶ Non-GMO

1) HCl = Hydrochloric acid; Source: WACKER Estimate

BioIngredients

WACKER is a Leading Supplier of Cyclodextrins Across Many Applications

Versatile Molecules from Renewable Raw Materials



We Address Consumer Trends by Providing Innovative Solutions

Cyclodextrin Capabilities

- ▶ World scale production set-up
- ▶ Sole producer of three types of cyclodextrins: 6 glucose units (α), 7 glucose units (β) or 8 glucose units (γ)

Benefits & Effects

- ▶ Stabilization: whipping and emulsifying
- ▶ Solubilization: improved bioavailability
- ▶ Controlled release: protect and carry
- ▶ Masking: taste masking




Applications

- ▶ Food, dietary supplements
- ▶ Pharma, excipients
- ▶ Personal care, pet care
- ▶ Household and industry

BiIngredients

Megatrends Driving Activities for Portfolio Expansion & Innovation

Expanding BiIngredients Portfolio Through Innovation & Emerging Applications

	End Markets	Market ¹	Trends & WACKER Solutions
	Nutraceuticals	7% p.a. ~€500bn	<ul style="list-style-type: none"> ▶ Healthy living & heart health trend ▶ LDL-cholesterol reduction, enhanced muscle recovery
	Functional food & Ingredients	6% p.a. ~€80bn	<ul style="list-style-type: none"> ▶ Vegan & white label trend ▶ Meat analogues, flavor masking & natural ingredients
	Dietary supplements	8% p.a. ~€130bn	<ul style="list-style-type: none"> ▶ Aging population trend ▶ Increase bioavailability & improve dispersibility

Sources: 1) Market growth and market size: Statista & WACKER Estimates

BioPharma

WACKER is a Leading Microbial CDMO


Cutting-Edge Technologies with a Proven Track Record in a Fast-Growing Market

Fast-Growing Market

Outsourcing on the Rise



Secretion Technology



Refolding Technology

Strong Track Record

Cutting-Edge Technologies



Live Microbial Products




mRNA and pDNA

BioPharma

Drivers for WACKER CDMO Business


Higher Outsourcing Rate¹ Drives Demand for CDMOs



Outsourcing is a tool for Big Pharma and Biotech alike to:

- ▶ Leverage advanced production technologies with high expertise
- ▶ Reduced risk & operational expenses

Microbial CDMO Market²




23%

WCH BioPharma:
Trailing 5 Year
Sales CAGR

- ▶ WACKER is committed to meet the industry's growing needs

#5 in a Fragmented Market



- ▶ Committed to grow faster than the market by capitalizing on organic & inorganic opportunities
- ▶ Leverage our innovative technology, flexibility and global set-up

Source: 1) Frost & Sullivan 2) Biopharmaceutical Contract Manufacturing 2020

BioPharma

Full-Service CDMO of Biologics with Cutting-Edge Technologies

Speed, Flexibility and Innovation in the Development & Manufacture of Biopharmaceuticals

WACKER



Supporting Customers with Leading Microbial Tech, Global Set-Up & Flexible Scale Production

Development

- ▶ Cutting-edge patented technologies
- ▶ Flexible and integrated solutions

Manufacturing

- ▶ Flexible scale production supporting Virtual Biotech to Big Pharma
- ▶ Supply from clinical to commercial
- ▶ Low COGS & high yields

Track Record

- ▶ >1,100 GMP batches released
- ▶ >200 projects successfully completed

BioPharma

Leading Technologies for the Production of Biopharmaceuticals

ESETEC®

- ▶ Unique manufacturing technology, with exceptionally high quality & flexibility
- ▶ No cell disruption needed, high yields & lower COGS



LIBATEC®

- ▶ Live microorganisms with therapeutic or preventive effects
- ▶ Development of scalable & fully closed mono-septic production processes



FOLDTEC®

- ▶ Manufacturing without any antibiotics and phage-free plasmid maintenance system
- ▶ Reduced COGS with efficient refolding



mRNA and pDNA manufacturing platforms


- ▶ mRNA - brand new production lines, ready to meet growing demand
- ▶ Proprietary continuous lysis platform for large-scale manufacturing of pDNA



BioPharma

Establish WACKER as a Leading mRNA & pDNA CDMO


Portfolio Expansion into Advanced Medicines Creates New Growth Opportunities




BioPharma

mRNA/pDNA Technologies Enable Advanced Therapies for Multiple Indications

mRNA CDMO Market¹ & Areas Researched²




- ▶ COVID-19 vaccines are just the first application, other therapeutics being researched



- ▶ mRNA for many applications
- ▶ 80+ vaccines & 70+ therapeutics in development

Fast Growing pDNA CDMO Market³



- ▶ Recent acquisition provides technology & large scale full GMP manufacturing of pDNA in the US
- ▶ pDNA - raw material for mRNA and for viral vector production





Source: 1) imarc Study 2020 & WACKER estimates 2) Roots mRNA Study 2020 3) Global Viral Vectors and Plasmid DNA Manufacturing Market Research Report

BioPharma

Creating a Leading Player with Strategic Acquisitions & Follow-On Investments

Global Set-Up with Cutting-Edge Technologies

2005	2008	2010	2014	2017	2018-21	2021
Jena: <i>ProThera</i> acquisition	Jena: New lab & warehouse	Jena: Extension of production	Halle: <i>Scil Proteins</i> acquisition & extension	Halle: Construction & modification	Amsterdam: <i>SynCo</i> acquisition & investment in mRNA	San Diego: Acquisition of <i>Genopis</i>

 <p>Jena</p> <ul style="list-style-type: none"> ▶ 350 L line ▶ Rec. proteins ▶ Cell banking ▶ EMA approved 	 <p>Halle</p> <ul style="list-style-type: none"> ▶ 1,500 L line ▶ Rec. proteins ▶ EMA & FDA approved 	 <p>Amsterdam</p> <ul style="list-style-type: none"> ▶ 250 SUB¹ & 1,500 L line ▶ Live microbial products, proteins, vaccines, mRNA ▶ EMA & FDA approved 	 <p>San Diego</p> <ul style="list-style-type: none"> ▶ 500 L line ▶ pDNA ▶ QC/QA for pDNA on site ▶ Small scale SUB ▶ GMP approved
---	---	--	--

1) SUB = Single Use Bioreactor

BIOSOLUTIONS

Strategic Focus & Roadmap

Accelerated Growth in BioPharma & BioIngredients

Unique Technology Platforms

- ▶ Cutting-edge technologies & strong scientific background
- ▶ Microbial technologies with exceptionally high quality, flexibility & low COGS



Customer Focus

- ▶ Strong global track record: pre-clinical to commercial manufacturing in BioPharma
- ▶ Leveraging our know-how, experience & assets to service customer



Commitment to Growth

- ▶ Continuous investments in innovation, growth and M&A
- ▶ €1bn Sales in BIOSOLUTIONS with >25% EBITDA by 2030



Q&A Session



Go to
www.slido.com
CMDJune2021

Q&A
?

WACKER: Virtual CMD Series Roadmap

June 2020

WACKER Strategy Update - Delivering on our 5 Targets



Dec 2020

SILICONES & POLYMERS - Specialties Growth & Performance Based Substitution



Today

BIOSOLUTIONS and R&D - Accelerated Growth with Cutting-Edge Technologies



Q4 2021

ESG & POLYSILICON - Leading CO₂ Abatement Technologies



Q1 2022

WACKER Strategy Update - Entering a New Phase with New Group Targets & Ambitions



WACKER: Issuer, Contact and Additional Information

Issuer and Contact

INVESTOR RELATIONS CONTACTS

Joerg Hoffmann, CFA

Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com

Scott McCollister

Tel. +49 89 6279 1560 | scott.mccollister@wacker.com

ISSUER

Wacker Chemie AG

Hanns-Seidel-Platz 4, D-81737 Munich
investor.relations@wacker.com

Additional Information



ISIN	DE000WCH8881
WKN	WCH888
Deutsche Börse	WCH

Financial Calendar

08/05/21	Q2 Results 2021
10/28/21	Q3 Results 2021
Q4 2021	Virtual CMD Series: ESG & POLYSILICON
Q1 2022	WACKER Strategy Update: New Group Targets & Ambitions

Publications




CUSTOMER
MAGAZINE



FACTBOOK



SUSTAINABILITY
REPORT



SQUARE
APP